Dutch Hospital Resumes Own Manufacture Of Leadiant’s Costly Drug
Aims To Address Steep Price Rise That Impairs Patient Access
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
You may also be interested in...
The US embassy in the Netherlands has attacked Dutch policies on compulsory licensing and compounding. Critics have accused it of scaremongering.
The US embassy in the Netherlands has attacked Dutch policies on compounding and compulsory licensing. Critics have accused it of scaremongering.
A new Dutch foundation set up to address cases of what it says are excessive drug pricing says it plans to refer Leadiant Biosciences’ CDCA product for the rare genetic disease, cerebrotendinous xanthomatosis, to the competition authorities.